Breast Cancer Index
PCR-based breast tumor gene-expression LDT providing distant-recurrence risk and likelihood of benefit from extended endocrine therapy.
- Developer
- Biotheranostics
- Intended use
- Risk Stratification
- Cancer scope
- Breast cancer
- Specimen
- Breast tumor tissue
- Molecular modality
- RNA expression
- Current version
- Breast Cancer Index current 2026 clinical LDT
- Evidence context
- 1 structured studies · 0 indexed performance results · 2 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.